Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapinarof in Palmoplantar Keratoderma
NCT06561321Phase 2Active, not recruiting
- Sponsor
- Indiana University
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tapinarof in palmoplantar keratoderma (PPK), sponsored by Indiana University. Primary endpoint: Physician's Global Assessment at 16 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
tapinarof
03
Conditions
palmoplantar keratoderma (PPK)
Beyond the preview
Go deeper on NCT06561321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561321.